S.Africa tackles drugs patent reform

South Africa's government has published a draft intellectual property policy with potential far-reaching effects for pharmaceutical patents, which rights groups hailed Monday as a move towards lower medicine costs.

If accepted, the reforms will facilitate the production of cheaper, generic medicines, according to Doctors Without Borders (MSF) and local AIDS-activist group Treatment Action Campaign.

The policies "set the stage for changes that promise to increase competition in the and lower the price of medicines in South Africa," the group said in a statement.

South Africa's current laws allow firms to renew patents indefinitely by changing minute elements in a medicine's composition.

"This allows companies to extend the life of their monopolies, block competition from , and charge inflated prices for medicines in both the public and private sector," said the rights groups.

The new patent policies will allow the production of and grant over five million South Africans living with AIDS or multi drug-resistant (MDR) tuberculosis access to treatments.

The country's powerful drug-makers treated the draft with caution.

"We would support anything that would increase IP (intellectual property) protection," said Val Beaumont, who heads the Innovative Pharmaceutical Association of South Africa.

The Department of Trade and Industry invited public consultation on the text until October 4, though the policy could take years to finalise.

According to the document, South Africa does not have a written national IP policy which has led to a fragmented approach to such matters.

add to favorites email to friend print save as pdf

Related Stories

Activists warn trade pact will keep out generics (Update)

Jul 03, 2013

A free trade pact being negotiated by the U.S. and 11 Asia-Pacific nations will impose aggressive intellectual property rules that could restrict access to affordable medicines in developing nations, health activists warned ...

India's top court to deliver Novartis judgment

Mar 31, 2013

India's Supreme Court is to rule Monday on a landmark patent case involving Swiss drugmaker Novartis AG that focuses on demands by major companies that their investments be protected, against Indian companies ...

Patents making new AIDS drugs expensive, MSF says

Jul 02, 2013

New potentially life-saving HIV drugs are "beyond reach" due to restrictive patents, Doctors Without Borders (MSF) said Tuesday, even though basic medication for the disease has become cheaper.

Recommended for you

Supercomputers link proteins to drug side effects

13 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

20 hours ago

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments